Executive Director, Dr. Kim Stephens, represented the Muenzer MPS Research & Treatment Center at the FDA Convening On the RISE: Controls in Rare Disease Clinical Trials for Small and Diminishing Populations workshop in Washington, D.C., hosted in partnership with the Duke-Robert J. Margolis, MD, Institute for Health Policy. This important meeting brought together leaders in research, clinical care, and patient advocacy to discuss new approaches that can improve rare-disease clinical trials. Dr. Stephens shared her expertise and highlighted the needs of the MPS community.
Read full event details: Duke-Margolis Institute for Health Policy.